Urotensin II induces transactivation of the epidermal growth factor receptor via transient oxidation of SHP-2 in the rat renal tubular cell line NRK-52E

References

• Ashton N. Renal and vascular actions of urotensin II. Kidney Int 2006; 70: 624–629
   PubMed Web of Science ®Google Scholar
• Chen CH, Cheng TH, Lin H, Shih NL, Chen YL, Chen YS, Cheng CF, Lian WS, Meng TC, Chiu WT, Chen JJ. Reactive oxygen species generation is involved in epidermal growth factor receptor transactivation through the transient oxidization of Src homology 2-containing tyrosine phosphatase in endothelin-1 signaling pathway in rat cardiac fibroblasts. Mol Pharmacol 2006; 69: 1347–1355
   Google Scholar
• Chen YL, Liu JC, Loh SH, Chen CH, Hong CY, Chen JJ, Cheng TH. Involvement of reactive oxygen species in urotensin II-induced proliferation of cardiac fibroblasts. Eur J Pharmacol 2008; 593: 24–29
   Google Scholar
• Chiarugi P, Cirri P. Redox regulation of protein tyrosine phosphatases during receptor tyrosine kinase signal transduction. Trends Biochem Sci 2003; 28: 509–514
   PubMed Web of Science ®Google Scholar
• Cook R, Wu CC, Kang YJ, Han J. The role of the p38 pathway in adaptive immunity. Cell Mol Immunol 2007; 4: 253–259
   PubMed Web of Science ®Google Scholar
• Djordjevic T, BelAiba RS, Bonello S, Pfeilschifter J, Hess J, Gorlach A. Human urotensin II is a novel activator of NADPH oxidase in human pulmonary artery smooth muscle cells. Arterioscler Thromb Vasc Biol 2005; 25: 519–525
   PubMed Web of Science ®Google Scholar
• Douglas SA, Sulpizio AC, Piercy V, Sarau HM, Ames RS, Aiyar NV, Ohlstein EH, Willette RN. Differential vasoconstrictor activity of human urotensin-II in vascular tissue isolated from the rat, mouse, dog, pig, marmoset and cynomolgus monkey. Br J Pharmacol 2000; 131: 1262–1274
   PubMed Web of Science ®Google Scholar
• Douglas SA, Dhanak D, Johns DG. From “gills to pills”: Urotensin-II as a regulator of mammalian cardiorenal function. Trends Pharmacol Sci 2004; 25: 76–85
   PubMed Web of Science ®Google Scholar
• Eguchi S, Dempsey PJ, Frank GD, Motley ED, Inagami T. Activation of MAPKs by angiotensin II in vascular smooth muscle cells. Metalloprotease-dependent EGF receptor activation is required for activation of ERK and p38 MAPK but not for JNK. J Biol Chem 2001; 276: 7957–7962
   PubMed Web of Science ®Google Scholar
• Gschwind A, Zwick E, Prenzel N, Leserer M, Ullrich A. Cell communication networks: Epidermal growth factor receptor transactivation as the paradigm for interreceptor signal transmission. Oncogene 2001; 20: 1594–1600
   PubMed Web of Science ®Google Scholar
• Kanda Y, Mizuno K, Kuroki Y, Watanabe Y. Thrombin-induced p38 mitogen-activated protein kinase activation is mediated by epidermal growth factor receptor transactivation pathway. Br J Pharmacol 2001; 132: 1657–1664
   Google Scholar
• Leserer M, Gschwind A, Ullrich A. Epidermal growth factor receptor signal transactivation. IUBMB Life 2000; 49: 405–409
   PubMedGoogle Scholar
• Liu KD, Brakeman PR. Renal repair and recovery. Crit Care Med 2008; 36: S187–S192
   PubMed Web of Science ®Google Scholar
• Matsushita M, Shichiri M, Imai T, Iwashina M, Tanaka H, Takasu N, Hirata Y. Co-expression of urotensin II and its receptor (GPR14) in human cardiovascular and renal tissues. J Hypertens 2001; 19: 2185–2190
   PubMed Web of Science ®Google Scholar
• Matsushita M, Shichiri M, Fukai N, Ozawa N, Yoshimoto T, Takasu N, Hirata Y. Urotensin II is an autocrine/paracrine growth factor for the porcine renal epithelial cell line, LLCPK1. Endocrinology 2003; 144: 1825–1831
   PubMed Web of Science ®Google Scholar
• Meng TC, Fukada T, Tonks NK. Reversible oxidation and inactivation of protein tyrosine phosphatases in vivo. Mol Cell 2002; 9: 387–399
   PubMed Web of Science ®Google Scholar
• Meng TC, Buckley DA, Galic S, Tiganis T, Tonks NK. Regulation of insulin signaling through reversible oxidation of the protein–tyrosine phosphatases TC45 and PTP1B. J Biol Chem 2004; 279: 37716–37725
   PubMed Web of Science ®Google Scholar
• Onan D, Pipolo L, Yang E, Hannan RD, Thomas WG. Urotensin II promotes hypertrophy of cardiac myocytes via mitogen-activated protein kinases. Mol Endocrinol 2004; 18: 2344–2354
   PubMed Web of Science ®Google Scholar
• Ong KL, Lam KS, Cheung BM. Urotensin II: Its function in health and its role in disease. Cardiovasc Drugs Ther 2005; 19: 65–75
   PubMed Web of Science ®Google Scholar
• Ravani P, Tripepi G, Pecchini P, Mallamaci F, Malberti F, Zoccali C. Urotensin II is an inverse predictor of death and fatal cardiovascular events in chronic kidney disease. Kidney Int 2008; 73: 95–101
   Google Scholar
• Salmeen A, Andersen JN, Myers MP, Meng TC, Hinks JA, Tonks NK, Barford D. Redox regulation of protein tyrosine phosphatase 1B involves a sulphenyl-amide intermediate. Nature 2003; 423: 769–773
   PubMed Web of Science ®Google Scholar
• Salmeen A, Barford D. Functions and mechanisms of redox regulation of cysteine-based phosphatases. Antioxid Redox Signal 2005; 7: 560–577
   PubMed Web of Science ®Google Scholar
• Sauzeau V, Le Mellionnec E, Bertoglio J, Scalbert E, Pacaud P, Loirand G. Human urotensin II-induced contraction and arterial smooth muscle cell proliferation are mediated by RhoA and Rho-kinase. Circ Res 2001; 88: 1102–1104
   PubMed Web of Science ®Google Scholar
• Saxton TM, Henkemeyer M, Gasca S, Shen R, Rossi DJ, Shalaby F, Feng GS, Pawson T. Abnormal mesoderm patterning in mouse embryos mutant for the SH2 tyrosine phosphatase Shp-2. Embo J 1997; 16: 2352–2364
   PubMed Web of Science ®Google Scholar
• Shah BH, Catt KJ. A central role of EGF receptor transactivation in angiotensin II -induced cardiac hypertrophy. Trends Pharmacol Sci 2003; 24: 239–244
   PubMed Web of Science ®Google Scholar
• Shenouda A, Douglas SA, Ohlstein EH, Giaid A. Localization of urotensin-II immunoreactivity in normal human kidneys and renal carcinoma. J Histochem Cytochem 2002; 50: 885–889
   PubMed Web of Science ®Google Scholar
• Song W, Abdel-Razik AE, Lu W, Ao Z, Johns DG, Douglas SA, Balment RJ, Ashton N. Urotensin II and renal function in the rat. Kidney Int 2006; 69: 1360–1368
   PubMed Web of Science ®Google Scholar
• Tibbles LA, Woodgett JR. The stress-activated protein kinase pathways. Cell Mol Life Sci 1999; 55: 1230–1254
   PubMed Web of Science ®Google Scholar
• Totsune K, Takahashi K, Arihara Z, Sone M, Satoh F, Ito S, Kimura Y, Sasano H, Murakami O. Role of urotensin II in patients on dialysis. Lancet 2001; 358: 810–811
   PubMed Web of Science ®Google Scholar
• Totsune K, Takahashi K, Arihara Z, Sone M, Murakami O, Ito S, Kikuya M, Ohkubo T, Hashimoto J, Imai Y. Elevated plasma levels of immunoreactive urotensin II and its increased urinary excretion in patients with type 2 diabetes mellitus: association with progress of diabetic nephropathy. Peptides 2004; 25: 1809–1814
   PubMed Web of Science ®Google Scholar
• Tzanidis A, Hannan RD, Thomas WG, Onan D, Autelitano DJ, See F, Kelly DJ, Gilbert RE, Krum H. Direct actions of urotensin II on the heart: implications for cardiac fibrosis and hypertrophy. Circ Res 2003; 93: 246–253
   PubMed Web of Science ®Google Scholar